Tudor Arvinte | President and Chief Executive Officer
Therapeomic Inc

Tudor Arvinte, President and Chief Executive Officer, Therapeomic Inc

Tudor Arvinte studied physics at University of Jassy, Romania, and received his Ph.D. in biophysics from University of Düsseldorf, Germany. He held numerous research positions in Europe and the USA at: Max-Planck Institute, Germany; C.N.R.S., France; Cornell University, New York; Texas A&M University; Ciba-Geigy U.K., Novartis, Switzerland. T. Arvinte worked with more than 200 biopharmaceuticals, three of his formulations reached the market, has over 90 publications and 15 patents. He is Titular Professor at Geneva University and CEO of Therapeomic, Inc. Basel Switzerland, a contract research biotech company focused on the characterization and formulation of biopharmaceuticals.


Biosimilars Day 2 - Wednesday 1st November 2017 @ 12:15

Importance of analytical methods for the success of biosimilars: case studies

  • Examples from the analytical and formulation work performed during the development of        
  • Biosimilars
  • Analytical challenges and the importance of new analytical methods
  • Formulation challenges and the importance of studies of aggregation in human plasma

back to speakers